Last reviewed · How we verify
NCT07537595
Efficacy of Cosmetic Products in Preventing Pigmentation Induced by High Energy Visible Light (HEVL) [400-450nm]
trial testing Treated and exposed zones (cosmetic topical products applied) in Skin Pigmentation in 33 participants. Completed in 6 December 2024.
6 December 2024
Quick facts
| Lead sponsor | Cosmetique Active International |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 10 June 2024 |
| Primary completion | 6 December 2024 |
| Estimated completion | 6 December 2024 |
| Sites | 1 location across Romania |
Drugs / interventions tested
- Treated and exposed zones (cosmetic topical products applied)
- Untreated and exposed zone (no product applied)
Conditions studied
- Skin Pigmentation — all drugs for Skin Pigmentation →
- Healthy Volunteers — all drugs for Healthy Volunteers →
- Hyperpigmentation — all drugs for Hyperpigmentation →
Sponsor
Cosmetique Active International — full company profile →
Who can join
Adults 18 to 60, any sex, with Skin Pigmentation or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this double-blind, randomized clinical trial is to evaluate the efficacy of anti-pigmentation cosmetic products in preventing skin pigmentation induced by High Energy Visible Light (HEVL) \[400-450nm\] in healthy volunteers (male and female, aged 18-60 years, Caucasian, phototypes III-IV). The main questions it aims to answer are: Can anti-pigmentation agents and/or HEV filters reduce HEV light-induced skin pigmentation, as measured by the Individual Typological Angle (Delta ITA°)? Can these products improve additional colorimetric parameters (Delta L\*, a\*, b\*, Delta E) and clinical pigmentation and erythema scores (0-13 scale)? Are these formulations safe and well-tolerated under HEVL exposure? Researchers will compare seven cosmetic formulations (Products A to G) to an untreated exposed control zone to assess their ability to prevent HEVL-induced pigmentation. Participants will: Attend 36 visits over 7 weeks Receive standardized product applications (2 mg/cm²) on 7 test zones (3x3 cm) delineated on their back. One test zone will be not treated. Be exposed to HEVL light \[400-450nm\] at 35 J/cm² over 4 consecutive days (Days 8-11) Undergo colorimetric measurements and clinical assessments of pigmentation and erythema at 13 time points
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07537595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Pigmentation
Currently open trials in the same condition.
- NCT06869252 — Autologous Adipose Cells Therapy · Phase 1, PHASE2 · recruiting
- NCT06142019 — Pulse Oximeter Accuracy in Healthy Humans During Hypoxia · recruiting
- NCT04875715 — Prospective Evaluation of Topical Almond Oil vs Hydroquinone · Phase 4 · recruiting
Other Cosmetique Active International trials
Trials by the same sponsor.
- NCT07239726 — CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPI · NA · not yet recruiting
- NCT06590779 — Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss · NA · not yet recruiting
- NCT06516224 — Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma · NA · not yet recruiting
- NCT06320314 — Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins · NA · unknown
- NCT06253455 — Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07537595 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cosmetique Active International
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07537595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing